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Abstract 
Increasing evidence suggests that small oligomers are the principal neurotoxic species of tau 
in Alzheimer’s disease and other tauopathies. However, mechanisms of tau oligomer-
mediated neurodegeneration are poorly understood. The transience of oligomers due to 
aggregation can compromise the stability of oligomers prepared in vitro. Consequently, we 
sought to develop an efficient method which maintains the stability and globular 
conformation of preformed oligomers. This study demonstrates that labeling a single-
cysteine form of the pro-aggregant tau four-repeat region (K18) with either Alexa Fluor 
488-C5-maleimide or N-ethylmaleimide in reducing conditions stabilizes oligomers by 
impeding their further aggregation. Furthermore, the use of this approach to study the 
propagation of labeled extracellular tau K18 oligomers into human neuroblastoma cells and 
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human stem cell-derived neurons is described. This method is potentially applicable for 
preparing stabilized oligomers of tau for diagnostic and biomarker tests, as well as for in 
vitro structure-activity relationship assays.  
 
Keywords 
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1.0 Introduction 
 
The gradual intracellular accumulation of tau aggregates into neurofibrillary tangles (NFTs) 
is a clinical hallmark for diagnosing and staging Alzheimer’s disease (AD) [1]. Nonetheless, 
tau pathology likely develops several years prior to symptom onset [2]. Indeed, cell death 
and synaptic lesions have been observed independent of NFT formation [3,4], prompting a 
need for tau biomarkers that better correlate with disease onset and progression [5]. 
Increasing evidence suggests that the activities of low molecular weight (LMW) oligomers, 
formed during the early stages of tau aggregation, most likely associate with neurotoxicity 
that leads to AD [6–8]. For example, tau oligomers induce mitochondrial, synaptic and 
memory defects [7] while insoluble filaments have been postulated to provide 
neuroprotective functions since they sequester toxic oligomers into inert filaments [9]. Many 
biochemical and toxicity studies of tau use oligomers produced from recombinant sources 
due to their ability to replicate important aggregative and pathophysiological effects of 
brain-derived tau oligomers [10–12]. However, the transient formation and subsequent 
aggregation of LMW tau oligomers present a daunting challenge for their preparation and 
characterization. Several tau oligomer preparation protocols, including those which have 
sought to address some of the existing difficulties, have been described [13–16]. 
Nonetheless, a critical persisting challenge is the stability of the resulting oligomers. For 
example, oligomeric forms of the central nervous system-specific full length (2N4R) tau 
isoform prepared by seeding monomer aggregation with preformed alpha synuclein or 
amyloid beta oligomers lose their stability and aggregate completely into filaments within 
48 hours of incubation [15]. This suggests that oligomers prepared in vitro are unstable and 
are prone to further aggregation, which may compromise experimental outcomes and 
reproducibility due to the distinct conformations that tau protein adopts at different stages of 
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the aggregation process [17,18]. This instability has previously been demonstrated for 
amyloid beta, another AD-linked protein, which is capable of undergoing detectable 
aggregation even when stored at an ultra-low temperature (-80 ºC) for long periods [19]. 
This suggests that instability is a major problem of the two most-characterized AD-
associated proteinopathic proteins when prepared in vitro.  
 
Tau aggregation occurs by two known mechanisms, namely: (i) cysteine-dependent 
polymerization through intermolecular disulfide bonding [20,21], and (ii) cysteine-
independent polymerization, occurring through the hexapeptide motifs (275VQIINK280, 
306VQIXXK311 and 337VEVKSE342) and non-covalent bonding [22–25]. Although either 
mechanism would in principle be sufficient, aggregation efficiency is increased in the 
presence of both [21]. In this study, it was hypothesized that labeling cysteine residues in 
tau monomers would extend the stability of the oligomers formed by blocking cysteine-
dependent aggregation. Since maleimide irreversibly binds cysteine residues, it was 
postulated that efficient labeling of cysteine residues (Fig. 1) would generate stable tau 
oligomers. Here, a simple approach of preparing stable LMW tau oligomers by labeling 
cysteine residues with commercially available derivatives of maleimide, namely Alexa 
Fluor 488-C5-maleimide (AF-maleimide) and N-ethylmaleimide (NEM), is described. 
Furthermore, the application of the fluorescence property of AF-maleimide-labeling to study 
the uptake of tau K18 oligomers by SH-SY5Y cells and human induced pluripotent stem 
cell (hiPSC)-derived neurons is described. 
 
2.0 Materials and methods 
 
2.1 Molecular biology and protein purification  
 
The pProEx-HTa-Myc-K18 plasmid used for the recombinant expression of tau K18 was 
used as previously described [26]. Cysteine modifications (C291A, C322A, I260C) were 
introduced into the encoded protein to prevent potential functional interference of the 
maleimide label. Site directed mutagenesis was performed and verified as previously 
described [26]. 6xHis/c-Myc-tagged K18 was transformed into and expressed in BL21 
(DE3)*pRosetta cells and the expressed protein purified using immobilized metal affinity 
chromatography following a previously-described protocol [26].  
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2.2 Preparation of labeled tau K18 oligomers 
 
Purified tau K18 was treated with 5x molar excess of tris(2-carboxyethyl)phosphine (TCEP) 
for 1 h, and then with 4x molar excess AF-maleimide (#A10254, Molecular Probes) or 
NEM (#23030, Thermo Scientific) overnight, in the presence of 10 mM sodium phosphate 
buffer pH 7.4. The protein was diluted in buffer to a  final concentration of 55 µM. Free 
fluorophore and reducing agent were removed by extensive dialysis against dialysis buffer 
(50 mM Tris HCl pH 7.5, 100 mM NaCl) in a Slide-A-Lyzer™ MINI Dialysis device (10K 
MWCO; Thermo Scientific), with the reservoir perforated and placed in a container large 
enough to accommodate a  2 L volume of buffer. The buffer was changed every 2 h for 10 
hours. Labeling was confirmed with non-denaturing sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) followed by ultraviolet light exposure. Labeling efficiency 
was measured spectrophotometrically using Beer’s law and the molar extinction coefficient 
of 72,000/cm/M for AF-maleimide. Unlabeled control samples were prepared identically 
except that equal volume of 10 mM sodium phosphate buffer pH 7.4 was used in place of 
the maleimide label. The entire labeling process was performed either at 4ºC or at room 
temperature (RT). 
 
 
2.3 Transmission electron microscopy (TEM) 
 
Formvar/carbon-coated 300-mesh copper grids (#S162, Agar scientific, UK) were glow-
discharged using the ELMO system from Cordouan Technologies. Five microliters of 
labeled or unlabeled K18 preparations were pipetted onto the grid and allowed to bind for 1 
min. Excess samples were removed with a strip of filter paper, and 5 µl of 2 % uranyl 
acetate added for 1 min. After removing the excess stain with a strip of filter paper, the grids 
were imaged using a JEOL-2100F transmission electron microscope. 
 
 
2.4 Dot blotting  
 
Each of the labeled and unlabeled control samples (27.5 µM) was mixed with 125 µM 
heparin, and incubated at 37 ºC in an Eppendorf Mastercycler gradient thermocycler for 48 
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h. Two microliter aliquots were spotted onto a piece of nitrocellulose membrane, air dried, 
blocked with 10 % non-fat milk in phosphate buffered saline (PBS) containing 0.05 % 
Tween for 30 min at RT, and subsequently washed five times with 10 % Tris buffered saline 
(TBS)-Tween. The membrane was incubated for 2 h with primary antibody (total tau 
#A0024, Dako or T22, Merck) and washed five times with 10 % TBS-Tween. The 
membrane was then treated with secondary antibody (anti-rabbit immunoglobulin G; 31450, 
Thermofisher) for a further 2 h. Antibodies were used at 1:1000 dilutions in the PBS-Tween 
buffer. Thereafter, the membrane was washed five times as previously, developed with an 
electrochemiluminiscent detection kit (Amersham), exposed to an X-ray film for 2 min and 
the blots developed in an AGFA Curix 60 processor (Agfa Healthcare, Greenville, SC, 
USA). Blot intensities were analyzed using ImageJ and the non-parametric data statistically 
compared with the Mann-Whitney test in GraphPad Prism 7 at the 95 % confidence interval.  
 
2.5 SH-SY5Y cell culture  
 
SH-SY5Y cells were purchased from Sigma Aldrich UK (#94030304) and maintained on 
1:1 minimal essential medium (MEM)/F12 Ham medium containing 1 % L-Glutamine, 15 
% foetal bovine serum, and 1 % antibiotic antimycotic acid (10,000 units penicillin, 10 mg 
streptomycin and 25 µg amphotericin B). All reagents were obtained from Sigma Aldrich. 
Cells between passages two and ten were used for all experiments. The cells were seeded at 
200,000 cells/ml in CellViewTM Advanced Tissue Culture dishes (#627975, Greiner Bio-
One) in the presence of AF-maleimide-labeled tau K18 oligomers dissolved in the culture 
medium to 5 µM. Following 24 h incubation at 37 ºC, 5 % CO2, the spent medium was 
removed, the cells washed with warm PBS and fresh tau-free medium containing 2 µM 
Hoechst 33342 (#H21492, Molecular Probes) and CellMask Deep Red (1:1000 dilution, 
#C10046, Thermofisher). Confocal microscopy imaging of internalized tau was performed 
after 30 min incubation at 37 ºC, 5 % CO2 using an LSM 710 microscope (Leica).  
 
 
2.6 hiPSC-derived cortical neurons  
 
Neural precursor cells (#ax0016) from cord blood CD34+ cells of a healthy, newborn 
female donor were purchased from Axol Bioscience, Cambridge, UK. Tissue culture grade 
12-well plates (Corning, New York, USA) were pre-coated with 250 µl/cm2 ReadySet 
reagent (Axol Bioscience), incubated at 37 ºC, 5 % CO2 for 45 min and rinsed four times 
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with double distilled water. Following this, Surebond reagent (Axol Bioscience) was diluted 
in Dulbecco’s PBS (DPBS), added to the plates at 200 µl/cm2 and incubated at 37 ºC, 5 % 
CO2 to equilibrate for 1 h. Next, stem cells were seeded at a low density (25,000 cells/cm2) 
on plasma-cleaned 13 mm glass coverslips, incubated at 37 ºC, 5 % CO2 and media changed 
every other day with Axol Neural Maintenance Medium kit (#ax0031, Axol Bioscience) for 
14-16 days prior to using the cells for experiments. Neuronal differentiation was monitored 
using phase contrast images obtained periodically with an EVOS XL Core Imaging System 
(Life Technologies) and the expression of neuron-specific markers monitored by 
immunohistochemistry (data not shown). Tau oligomers were diluted to 5 µM in Axol 
Neural Maintenance medium, supplied to neurons and then incubated for 24 h at 37 ºC, 5 % 
CO2.  After removing the spent medium, the neurons were washed with DPBS, and new 
medium added.  
 
Neurons were then fixed for 30 min with 4 % paraformaldehyde, washed two times with 
DPBS, and rinsed with permeabilizing solution (DPBS containing 0.2 % Triton). 
Afterwards, the fixed neurons were incubated for 1 h in blocking buffer (DPBS with 0.2 % 
Triton and 2 % BSA). This was followed by another 1 hour incubation in the blocking 
buffer containing primary antibody and Hoechst. Excess antibody was removed by washing 
thrice with blocking buffer only for 5 min each time. Subsequently, the neurons were 
incubated in blocking buffer containing secondary antibody for 1 h, and the blocking buffer 
wash steps repeated. Next, the slides were rinsed with distilled water and dropped into 
ProLong Gold Antifade mounting medium (#P36934, ThermoFisher Scientific). Neurons 
were imaged with a Leica STP 6000 confocal microscope after at least 24 h of curing. 
 
 
3.0 Results and Discussion 
 
This study used the K18 fragment (tau microtubule (MT) binding region; residues 244 – 
372), since a demonstration of oligomer stability for this aggregation-prone functional tau 
region would in principle make the method applicable to the full-length isoforms which are 
less aggregation-prone [27] and may therefore be easier to stabilize. Due to their close 
proximity to residues that directly bind MTs [28], the two native cysteine residues in tau 
K18 were modified to alanine and a new one introduced at the N-terminus of the MT-
binding region (see the Materials and Methods section). This approach was to ensure 
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efficient labeling of a single cysteine residue without potential interference of MT binding 
[17,29,30]. 
 
The K18 tau construct was cloned into pProEx, transformed into BL21 (DE3) Escherichia 
coli, expressed, purified and biochemically characterized as described [26]. Oligomers were 
prepared by initially treating freshly-purified proteins with the reducing agent TCEP for 1 h 
to ensure all proteins were monomeric. Thereafter, the exposed sulfhydryl groups were 
labeled with AF-maleimide and the reaction allowed to proceed at 4 ºC overnight followed 
by extensive dialysis to remove excess dye and TCEP. This “monomerization-labeling-
oligomerization” strategy ensured accessibility of the labeling site to the maleimide dye. 
The overnight incubation allowed for limited aggregation of labeled monomers into LMW 
oligomers. Control samples labeled without TCEP treatment lacked the uniform oligomer 
distribution observed in those TCEP-treated before labeling (Fig. 2). The labeled proteins 
aggregated into globular, LMW oligomers (Fig. 3), akin to what is found in the brains of 
AD patients [6] and those reported from other recombinant tau oligomerization protocols 
[15]. No discernible difference in oligomerization patterns was observed between the 
labeled and unlabeled proteins (Fig. 3) as all samples were capable of  forming oligomers. 
However, oligomers assembled from unlabeled tau K18 were unstable as explained below.  
 
To test the hypothesis that cysteine labeling interferes with tau aggregation, the AF-
maleimide labeled oligomers and unlabeled controls were challenged with the aggregation 
inducer heparin and heated at 37 ºC without shaking for 48 h. After incubation, aliquots 
were taken from each sample following quick mixing and analyzed by negative-stain TEM. 
The labeled proteins existed mostly as globular oligomers (Fig. 4A), appeared mainly 
trimeric/tetrameric in distribution (Fig. 2A), and were of similar structure as those imaged 
prior to heparin and heat treatment (Fig. 3B). By contrast, the unlabeled protein underwent 
further aggregation to form mature insoluble filaments, via intermediate protomers and 
early-stage filaments (Fig. 4B). These results indicate that AF-maleimide labeling stabilizes 
tau oligomers and prevents their aggregation and conformational change into paired helical 
filaments.  
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Performing the reaction under cold conditions appeared critical to the success of the new 
method. Contrary to the dominance of globular oligomers when labeled at 4 ºC (Figs. 3 and 
4), a mixture of globular oligomers and fibrils was observed when the reaction was 
performed at RT (Fig. S1). This phenomenon may be explained by the higher labeling 
efficiency at 4 ºC compared to at RT (97% and 82.5% respectively); there is a much higher 
proportion of unlabeled starting material at RT capable of aggregating into fibrils. This data 
is in agreement with previous reports showing high AF-maleimide labeling efficiencies at 4 
ºC [31,32], and also explains why fibrils can be detected among tau proteins labeled at RT 
or 37 ºC [29,30]. 
 
 
Next, we asked if the observed oligomer-stabilizing property of AF-maleimide was shared 
by other maleimide derivatives. For this reason, the alkylating agent NEM which reacts in a 
similar mechanism as AF-maleimide with sulfhydryls to form stable thioesters was tested. 
NEM labeling of tau K18 was performed as described for AF-maleimide. To test their 
stability, the formed oligomers were treated with heparin, incubated at 37 ºC for 48 h and 
thereafter characterized by TEM. It was observed that, like AF-maleimide, NEM labeling 
stabilized tau oligomers also blocked further aggregation into filaments (Fig. 5A and B).  
 
Subsequently, the effect of maleimide labeling on the conformation of tau K18 oligomers 
was investigated. The immunoreactivity of oligomer preparations labeled with AF-
maleimide or NEM were probed with an oligomer conformation-specific antibody (T22) 
and a total tau antibody (A0024, Dako) as a control in dot blotting experiments. Oligomers 
labeled using either method gave near-identical total tau reactivity to the unlabeled control 
(Figs 6 and 7). However, the labeled proteins were consistently less reactive to the T22 
antibody (Mann Whitney test, p < 0.05 in both cases; Figs 6 and 7). This suggests that the 
conformation of the unlabeled tau K18 oligomers recognized by the T22 antibody was 
altered by the maleimide labeling. A few reasons could have accounted for this reduced 
recognition. Firstly, the maleimide labels may have masked the antibody epitope thereby 
reducing accessibility and binding of the antibody. A similar outcome has recently been 
reported from a pharmacological inhibition of tau oligomer aggregation where binding of 
the phenothiazine compound Azure C also reduced T22 reactivity [33]. Secondly, the 
antibody preferably recognises larger oligomers over LMW oligomers, such as those found 
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in the labeled samples. As the unlabeled samples aggregated further into fibrils, it can be 
postulated that they may have consisted of larger pools of higher molecular weight 
oligomers which would be responsible for their stronger reactivity. T22 is thought to 
selectively recognize non-fibrillar tau oligomers [8] but it may not be able to discriminate 
between oligomers of different sizes which share the same conformational epitope. The 
stronger immuno-reactivity recorded for the unlabeled samples may be due to differences in 
non-fibrillar aggregated proteins compared to the labeled (Figs. 6 and 7). Thirdly, since the 
T22 antibody can also cross-react with fibrils [8], the presence of fibrils in the unlabeled 
samples may have increased the reactivity of the T22 antibody in the unlabeled samples. As 
the only difference between the labeled and the unlabeled tau K18 samples was the extent of 
aggregation as evidenced by TEM analysis, it can be concluded that AF-maleimide labeling 
reduces reactivity of tau K18 oligomers to the T22 conformation-dependent antibody, which 
may be due to their restricted aggregation. This finding along with those of others [32] 
suggests care should be taken when assessing oligomerization using the T22 antibody alone. 
 
A mechanism proposed for the propagation of AD pathology is the transmission of toxic tau 
proteins from one neuron to the other in specific brain regions [34–36]. A critical step in this 
inter-neuronal transmission model is the uptake of extracellular tau into neighboring 
neurons, followed by their interaction with endogenous proteins and subsequent release of 
the resulting aggregates to initiate new internalization cycles [34–36]. For better 
understanding of the molecular cascade of events occurring in this process, real-time 
microscopic visualization of live cells treated with tau is necessary. As oligomers are 
thought to be a crucial species regulating the inter-neuronal transmission of tau pathology 
[6,8,10,11], the molecular fluorescence property of AF-maleimide was used to study the 
internalization of stabilized extracellular tau K18 oligomers into cultured SH-SY5Y human 
neuroblastoma cells. AF-maleimide oligomers were prepared as described above, diluted in 
extracellular medium to 5 µM final concentration, supplied exogenously to cultured cells 
and incubated for 24 h. Subsequently, the spent medium was removed, the cells washed 
with warm phosphate buffered saline to remove non-internalized tau and new tau-free 
medium containing nuclear and cell membrane markers added. The internalized tau was 
then visualized using confocal microscopy. Remarkably, internalization of fluorescent 
extracellular tau was observed, with cells containing these internalized proteins exhibiting 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
10
diverse morphological phenotypes: in some cells diffused cytoplasmic distribution of 
labeled protein was observed, with more localized punctate staining in other cells (Fig. 8A). 
These phenotypes were similar to those reported for labeled tau K18 internalized in the 
same neuroblastoma cell line [30], as well as other human cell lines [37]. To extend the use 
of these fluorescently labeled oligomers toward a more physiologically-relevant neuronal 
model, hiPSC-derived cortical neurons were prepared and seeded with 5 µM extracellular 
tau oligomers. Following 24 incubation, the neurons were fixed using paraformaldehyde. 
Maximum projection of z-stack confocal microscopy images revealed that tau oligomer 
internalization likely occurs by endocytosis (as oligomers were encapsulated by the 
vesicular marker FM4-64®) and that the inclusions accumulated both in the cell soma and 
neurites, hence providing insights into the subcellular localization of tau oligomer inclusions 
in addition to their morphological phenotypes (Fig. 8B). Together, these findings 
demonstrate that maleimide stabilization offers a unique strategy for the characterization of 
cellular internalization of tau oligomers and to screen for therapeutic agents against this 
disease-relevant process.  
 
Here, we have demonstrated that efficient labeling of tau K18 with AF-maleimide or NEM 
provides the advantage of stabilizing the resulting oligomers. Interestingly, a recent study by 
Chen et al., (2018) has corroborated our findings, showing that NEM labeling of the single 
cysteine residue at amino acid position 322 of the shortest tau isoform in the adult human 
brain (0N3R) prevents its H2O2-induced aggregation [38]. Our proposed strategy (Fig. 9) 
ensures that preformed tau oligomers remain in their desired authentic oligomeric state for 
extended periods of time, offering an exceptional opportunity to advance downstream 
investigations into the biochemical, biophysical and neurobiological aspects of the 
association between tau aggregation and neurodegeneration. Moreover, the method is 
simple, time-efficient and does not require expensive pre- and post-treatment stages. The 
proposed approach is potentially applicable to brain-derived tau oligomers, and can support 
studies of mechanistic and conformational changes in tau oligomers that may alter the 
protein’s neurotoxicity and drug-reactivity profiles. Additionally, the method can likely be 
extended to other proteinopathic proteins containing cysteine residues, such as huntingtin 
and cysteine-containing amyloid beta [39]. We have applied this approach to obtain novel 
insights into the subcellular internalization and neuronal transmission of exogenous tau K18. 
This has allowed an analysis of the effects of tau mutant variants implicated in diseases such 
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as frontotemporal dementia on the protein’s neuronal internalization. Our results indicate 
that this method provides a quick and reliable approach of monitoring cellular 
internalization of exogenous proteins in real time, and therefore offers an advantage over 
other fluorescent tags especially for small proteins like tau K18. Furthermore, the neuronal 
uptake and secretion of extracellular tau oligomers are thought to be regulated by protein-
cell membrane interactions, details of which are still unclear [40,41]. This oligomer 
stabilization strategy offers a straightforward approach to study conformational and 
aggregation dynamics of protein-membrane interactions both at the single and bulk 
molecular levels using fluorescent spectroscopy and cell biology techniques. Additionally, 
stabilized oligomers are good immunogen candidates for antibody production against tau 
oligomer-targeted immunotherapy.  
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Figure Legends  
 
Fig. 1. Schematic illustration of maleimide conjugation to the tau K18 protein.  
(A) Molecular structure of AF-maleimide, as provided by the vendor [42]. (B) Molecular 
structure of NEM. (C) Illustration of the reaction of the maleimide functional group of AF-
maleimide with the sulfhydryl group of tau K18 to produce a stable thioether conjugate. (D) 
Illustration of the specific binding of NEM with the sulfhydryl group of tau K18 to produce 
a tau K18-NEM conjugate.  
 
Fig. 2. Representative non-denaturing SDS-PAGE images demonstrating the outcome 
of AF-maleimide labeling of tau K18 in reducing and non-reducing conditions. 
Migration of tau K18 labeled with AF-maleimide with (A) or without (B) prior TCEP 
treatment. The figures show representative (n = 3) non-denaturing SDS-PAGE analysis of 
tau aggregate patterns in the two labeling methods. 
 
Fig. 3. Structural characterization of tau K18 oligomers stabilized by labeling with 
maleimide derivatives.  Representative TEM micrographs of globular tau K18 oligomers 
prepared: (A) without labeling, (B) with AF-maleimide labeling, or (C) with NEM labeling. 
Scale bars = 50 nm for all images.  
 
Fig. 4. Labeling with AF-maleimide stabilizes tau K18 oligomers. (A) Representative 
electron micrographs of AF-maleimide-labeled tau K18 structures identified after co-
incubation with heparin at 37 ºC for 48 hours. Figures A(i) and A(ii) show globular 
oligomers with different degrees of negative staining. (B) Representative TEM micrographs 
of aggregates identified for the unlabeled control samples treated similarly to the test 
samples. Globular oligomers (i), protomers (ii), short and mature fibrils (iii and iv 
respectively) were observed, suggesting heparin-induced structural transition to form fibrils. 
n = 2, with images taken from at least 5 different areas of each TEM grid. Scale bars = 100 
nm for all images.  
 
Fig. 5. NEM labeling stabilizes tau K18 oligomers in their globular conformation. 
NEM-labeled and unlabeled control tau K18 samples were each incubated with heparin at 
37 ºC for 48 hours, and aliquots analyzed using negative-stain TEM. (A) Representative 
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TEM micrographs of NEM-labeled tau K18 aggregates. The globular nature of these non-
fibrillar aggregates in A(i) and A(ii) suggests oligomer stabilization. (B) Representative 
TEM micrographs of endpoint samples demonstrating the presence of unlabeled tau K18 
into oligomers, protomers, short and mature fibrils. n = 2, with images taken from at least 5 
different areas of each grid. Scale bars = 100 nm for all images.  
 
Fig. 6. Immunological analysis of the conformation of AF-maleimide-labeled tau K18 
oligomers using dot blotting. (A) Representative dot blot data for the reactivity of labeled 
and unlabeled tau K18 to two tau antibodies (A0024, top panel) and T22 (bottom panel). (B) 
Semi-quantitative analysis of dot blot intensity using Image J. UNL = unlabeled; MAL = 
AF-maleimide labeled. Mann Whitney test, * = p<0.05, ns = not significant (n = 4). Data 
expressed as mean ± standard deviation.  
 
Fig. 7. Dot blot analysis of the conformation of NEM-labeled tau K18 oligomers.  
(A) Representative dot blot data for the immuno-reactivity of labeled and unlabeled tau K18 
to two tau antibodies (A0024, top panel) and T22 (bottom panel). (B) Semi-quantitative 
analysis of dot blot intensity using Image J. UNL = unlabeled; NEM = NEM labeled. Mann 
Whitney test, * = p<0.05, ns = not significant (n = 4). Data expressed as mean ± standard 
deviation.  
 
Fig. 8. Extracellularly-applied tau K18 oligomers are internalized by SH-SY5Y 
neuroblastoma cells and hiPSC-derived neurons.  (A) Internalization of AF-maleimide-
labeled tau K18 oligomers in SH-SY5Y neuroblastoma cells. (B) Internalization of 
extracellular oligomers was also studied in hiPSC-derived neurons, revealing their 
localization both in neurites and the cell soma. Scale bars = 10 µm for all images.  
 
Fig. 9. Schematic illustration of the facile method of tau oligomer stabilization 
described in this study. The method involves first treating highly-purified monomers with 
the reducing agent TCEP to monomerize apparent oligomers. Monomers are then labeled 
overnight with either maleimide derivative (AF-maleimide or NEM), followed by removal 
of excess fluorophore by dialysis. Labeled oligomers can then be characterized using an 
array of biochemical and biophysical tools, including non-denaturing SDS-PAGE, 
dot/Western blotting and TEM. Oligomer stabilization can be studied by inducing 
aggregation with heparin and studying the structures and conformation of the aggregates 
formed by TEM and dot blotting respectively, or by similar techniques. 
 
Supplementary data  
 
Fig. S1. AF-maleimide labeling of tau K18 at RT generates a mixture of globular 
oligomers and fibrillar aggregations. (A) Representative TEM micrographs of tau K18 
labeled with AF-maleimide at RT showing presence of both globular oligomers and fibrils 
(shown by arrows). (B) Unlabeled control tau K18 samples aggregated into a range of pre-
fibrillar and fibrillar structures. Scale bars = 100 nm.  
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Highlights 
• The transient nature of tau aggregation makes it difficult to maintain the stability of 
preformed oligomers  
• Efficient labeling of tau K18 with Alexa Fluor-488-C5-maleimide or N-ethyl 
maleimide stabilizes the resulting oligomers. 
• Oligomers applied exogenously are propagated intracellularly by cultured human 
iPSC neurons and neuroblastoma cells. 
• Oligomer preparation by maleimide labeling offers unique opportunities for studying 
the mechanistic and conformational bases of tau aggregation, and its link to 
neurodegeneration. 
 
